North-America age-related macular degeneration (AMD) market is projected to register a CAGR of 8.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
Market Segmentation:
North-America Age-Related Macular Degeneration (AMD) Market, By Types (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others) and Distribution Channel (Direct Tender and Retail Sales) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the North-America age-related macular degeneration (AMD) market are:
Growing geriatric population
Growing prevalence of macular degeneration
Market Players:
The key market players for North-America age- related macular degeneration (AMD) market are listed below:
Novartis AG
Bayer AG
REGENXBIO Inc.
Ionis Pharmaceutics
Ocugen Inc
Johnson & Johnson Services, Inc
IVERIC bio
MeiraGTx Limited
Adverum Biotechnologies, Inc.
Graybug Vision Inc.
Kodiak Sciences Inc.
Genentech Inc.
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 OVERVIEW OF NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET 13
1.4 LIMITATIONS 15
1.5 MARKETS COVERED 15
2 MARKET SEGMENTATION 18
2.1 MARKETS COVERED 18
2.2 GEOGRAPHICAL SCOPE 19
2.3 YEARS CONSIDERED FOR THE STUDY 20
2.4 CURRENCY AND PRICING 20
2.5 DBMR TRIPOD DATA VALIDATION MODEL 21
2.6 MULTIVARIATE MODELLING 24
2.7 TYPE LIFELINE CURVE 24
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 25
2.9 DBMR MARKET POSITION GRID 26
2.10 MARKET END USER COVERAGE GRID 27
2.11 VENDOR SHARE ANALYSIS 28
2.12 SECONDARY SOURCES 29
2.13 ASSUMPTIONS 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 33
4.1 PESTEL 34
4.2 PORTER'S FIVE FORCES MODEL 35
5 REGULATORY FRAMEWORK 36
6 MARKET OVERVIEW 39
6.1 DRIVERS 41
6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION 41
6.1.2 INCREASING GERIATRIC POPULATION 41
6.1.3 INCREASE IN PIPELINE PRODUCTS 42
6.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS 43
6.2 RESTRAINTS 43
6.2.1 HIGH COST OF TREATMENT AND PROCEDURES 43
6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS 44
6.3 OPPORTUNITIES 45
6.3.1 INCREASING RESEARCH AND DEVELOPMENT 45
6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD 45
6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT 46
6.3.4 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD) 46
6.4 CHALLENGES 47
6.4.1 LIMITED ACCESS TO TREATMENT 47
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS 47
7 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE 48
7.1 OVERVIEW 49
7.2 DRY AMD 52
7.3 WET AMD 52
7.3.1 MEDICATIONS 53
7.3.2 ANTI-VEGF THERAPY 54
7.3.3 GENE THERAPY 54
7.3.4 SURGERY 54
8 NORTH AMERICA AGE- RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER 55
8.1 OVERVIEW 56
8.2 HOSPITALS 59
8.3 SPECIALTY CLINICS 59
8.4 AMBULATORY SURGICAL CENTERS 60
8.5 HOME HEALTHCARE 61
8.6 OTHERS 62
9 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL 63
9.1 OVERVIEW 64
9.2 RETAIL SALES 68
9.2.1 HOSPITAL PHARMACIES 69
9.2.2 RETAIL PHARMACIES 69
9.2.3 OTHERS 69
9.3 DIRECT TENDER 69
10 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION 70
10.1 NORTH AMERICA 71
10.1.1 U.S. 77
10.1.2 CANADA 79
10.1.3 MEXICO 81
11 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY LANDSCAPE 83
11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 83
12 SWOT ANALYSIS 84
13 COMPANY PROFILE 85
13.1 NOVARTIS AG 85
13.1.1 COMPANY SNAPSHOT 85
13.1.2 REVENUE ANALYSIS 85
13.1.3 COMPANY SHARE ANALYSIS 86
13.1.4 PRODUCT PORTFOLIO 86
13.1.5 RECENT DEVELOPMENT 86
13.1.5.1 AGREEMENT 86
13.2 GENENTECH, INC. 87
13.2.1 COMPANY SNAPSHOT 87
13.2.2 COMPANY SHARE ANALYSIS 87
13.2.3 PRODUCT PORTFOLIO 88
13.2.4 RECENT DEVELOPMENT 88
13.3 BAYER AG 89
13.3.1 COMPANY SNAPSHOT 89
13.3.2 REVENUE ANALYSIS 89
13.3.3 COMPANY SHARE ANALYSIS 90
13.3.4 PRODUCT PORTFOLIO 90
13.3.5 RECENT DEVELOPMENT 90
13.4 ADVERUM BIOTECHNOLOGIES, INC. 91
13.4.1 COMPANY SNAPSHOT 91
13.4.2 REVENUE ANALYSIS 91
13.4.3 PRODUCT PORTFOLIO 91
13.4.4 RECENT DEVELOPMENT 92
13.5 ASTELLAS PHARMA INC. 93
13.5.1 COMPANY SNAPSHOT 93
13.5.2 REVENUE ANALYSIS 93
13.5.3 PRODUCT PORTFOLIO 94
13.5.4 RECENT DEVELOPMENT 94
13.6 GRAYBUG VISION INC. 95
13.6.1 COMPANY SNAPSHOT 95
13.6.2 REVENUE ANALYSIS 95
13.6.3 PRODUCT PORTFOLIO 95
13.6.4 RECENT DEVELOPMENT 96
13.7 GENSIGHT BIOLOGICS 97
13.7.1 COMPANY SNAPSHOT 97
13.7.2 REVENUE ANALYSIS 97
13.7.3 PRODUCT PORTFOLIO 98
13.7.4 RECENT DEVELOPMENTS 98
13.7.4.1 EVENT 98
13.7.4.2 AWARD 98
13.8 IONIS PHARMACEUTICALS 99
13.8.1 COMPANY SNAPSHOT 99
13.8.2 REVENUE ANALYSIS 99
13.8.3 PRODUCT PORTFOLIO 100
13.8.4 RECENT DEVELOPMENT 100
13.8.4.1 EVENT 100
13.9 IVERIC BIO 101
13.9.1 COMPANY SNAPSHOT 101
13.9.2 PRODUCT PORTFOLIO 101
13.9.3 RECENT DEVELOPMENT 101
13.10 JOHNSON &JOHNSON SERVICES, INC. 102
13.10.1 COMPANY SNAPSHOT 102
13.10.2 REVENUE ANALYSIS 102
13.10.3 PRODUCT PORTFOLIO 103
13.10.4 RECENT DEVELOPMENT 103
13.10.4.1 COLLABORATION 103
13.11 KODIAK SCIENCES INC. 104
13.11.1 COMPANY SNAPSHOT 104
13.11.2 PRODUCT PORTFOLIO 104
13.11.3 RECENT DEVELOPMENT 104
Short Description
North America Age-Related Macular Degeneration (AMD) Disease Market, By Type (Dry AMD and Wet AMD) End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others) Distribution Channel (Direct Tender and Retail Sales) Country (U.S., Canada ,Mexico)Industry Trends and Forecast to 2029
Market Definition:
Age-related macular degeneration (AMD) is an eye disease that can cause damage to the macula part of the eye that controls sharp and straight-ahead vision. This leads to blurred central vision. Vision loss that can be caused by abnormal blood vessel growth. Macular degeneration is more common in aging people. The diagnosis of disease is possible at various stages and number of genetic testing and retinal imaging are some of the techniques for the detection of disease. The diagnosis of the disease is conducted mainly by optical imaging techniques and other standard processes.
Age-related macular degeneration (AMD) can cause damage to the macula part of the eye. This leads to blur central vision. It can cause irreversible blindness and is the leading cause of visual impairment in the elderly people.The diagnosis and treatment of age-related macular degeneration (AMD) disease consist of various techniques that allow diagnosis of disease after the approval of the product. The treatment for the disease is recently approved which support the market growth. However, these treatments are expensive and not available to all the patients in many countries.
Market Segmentation:
North America age-related macular degeneration (AMD) disease market is categorized into three notable segments such as type, end user, and distribution channel.
On the basis of type, the North America age-related macular degeneration (AMD) disease market is segmented into dry AMD and wet AMD
On the basis of end user, the North America age-related macular degeneration (AMD) disease market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare and others
On the basis of distribution channel, the North America age-related macular degeneration (AMD) disease market is segmented into direct tenders and retail sales
Market Players
The key market players for North America age-related macular degeneration (AMD) disease Market are listed below:
Novartis AG
Bayer AG
REGENXBIO Inc.
Ionis Pharmaceutics
Ocugen Inc
Johnson & Johnson Services, Inc
IVERIC bio
MeiraGTx Limited
Adverum Biotechnologies, Inc.
Graybug Vision Inc.
Kodiak Sciences Inc.
Genentech Inc.
Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
